Strut BBB and Consumer-Complaint Trends: What Patients Should Know

What Is Strut Health and How Does Its Model Work?

Strut Health operates as an asynchronous telehealth platform that connects patients with licensed prescribers and routes prescriptions to compounding pharmacies, primarily for finasteride, minoxidil, tretinoin, and sildenafil-based formulas. The platform does not manufacture medications itself. Instead, it works with 503A-designated compounding pharmacies regulated under the Drug Quality and Security Act of 2013.

The 503A Compounding Framework

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may prepare compounds for individual patients based on a valid prescription without full FDA pre-market approval. That exemption comes with specific conditions: the compound must be based on a valid patient-specific prescription, must not be essentially a copy of a commercially available drug in most circumstances, and the pharmacy must comply with USP standards for sterile or non-sterile preparations.

The FDA publishes a list of 503B outsourcing facilities separately. Patients using Strut should confirm whether their dispensing pharmacy holds 503A or 503B status, since the oversight requirements and inspection frequency differ substantially.

Why the Business Model Matters for Complaint Interpretation

Many complaints filed against telehealth compounders conflate the platform (Strut's website and prescribers) with the pharmacy partner. A billing complaint may originate with Strut's subscription software; a medication quality complaint may originate with the dispensing pharmacy. Distinguishing these two entities is essential when reading BBB filings or state board records.

Strut's BBB Profile: What the Data Actually Shows

The Better Business Bureau collects consumer complaints and grades businesses on a scale of A+ to F, weighting factors that include complaint volume relative to business size, complaint resolution rate, and time in business. BBB accreditation is a paid membership that signals a business has agreed to BBB standards; it does not equal regulatory approval.

Current Rating and Complaint Volume

Strut Health's BBB profile (search at bbb.org) has historically shown a small-to-moderate complaint count for a telehealth company of its size. BBB grades can fluctuate month to month as complaints are filed and closed. Because this article is reviewed and updated by the HealthRX medical team, readers should check the live BBB profile directly rather than relying on any static screenshot.

The FTC's guidance on reading BBB ratings notes that a high letter grade does not mean a business is free of problems. A grade can remain high if complaints are formally closed, even when the resolution was disputed by the consumer.

Recurring Complaint Categories

Across publicly available BBB filings and consumer-review aggregators, Strut complaints cluster into four categories:

1. Shipping and fulfillment delays. Patients report waiting longer than the estimated 5-to-10 business days, particularly for minoxidil formulations that require compounding on demand.
2. Subscription billing disputes. Auto-renewal charges after patients believed they had canceled are the single most frequently cited issue in consumer narratives.
3. Prescription transfer difficulty. Some patients report difficulty obtaining a written copy of their prescription to take to a local pharmacy.
4. Refund processing time. Refunds taking 10-to-21 business days appear in multiple complaint threads.

How Strut Has Responded

BBB complaint responses from Strut typically acknowledge the issue, offer refunds or replacement shipments, and mark cases as resolved. A business that responds and resolves complaints at a high rate will maintain a better BBB score even if underlying operational issues persist. The response pattern alone does not confirm that systemic problems have been corrected.

Is Strut Legit? Regulatory Standing Beyond the BBB

The BBB is a private nonprofit, not a government regulator. Legitimate regulatory markers for a telehealth compounding platform include state pharmacy board licensing, FDA inspection history, and LegitScript certification.

State Pharmacy Board Licensing

Strut's compounding pharmacy partners must hold active licenses in each state where they dispense. Patients can verify pharmacy licenses through the National Association of Boards of Pharmacy (NABP) database. NABP also maintains a "Not Recommended" list of online pharmacies that do not meet U.S. Licensing standards.

California, where Strut is headquartered, requires telehealth platforms that support prescriptions to comply with the Medical Board of California's telehealth standards and the California State Board of Pharmacy rules for prescriptions generated via asynchronous questionnaires. The California State Board of Pharmacy posts disciplinary actions publicly.

FDA Inspection and Warning Letter History

The FDA publishes warning letters to compounding pharmacies that violate cGMP standards, use non-bulk drug substances, or produce drugs on the FDA's Difficult to Compound list. As of the most recent HealthRX review, no FDA warning letter has been identified specifically naming Strut Health or its named pharmacy partner. Patients should independently search the FDA warning-letter database using the pharmacy's legal name before ordering.

The FDA's 2023 guidance on compounded semaglutide became relevant for platforms offering GLP-1 compounds; Strut does not currently list semaglutide among its core offerings, but the guidance illustrates how quickly the regulatory picture around compounders can change.

LegitScript Certification

LegitScript is an independent verification service that the FDA and major payment processors recognize as a standard for online pharmacy legitimacy. A LegitScript-certified pharmacy has demonstrated licensed status, requires valid prescriptions, and does not sell controlled substances without a prescription. Patients can run a search at LegitScript.com using Strut's domain or its pharmacy partner's name.

The HealthRX verification framework for any compounding telehealth platform uses four parallel checks: (1) NABP database for the dispensing pharmacy's license, (2) FDA warning-letter search for the pharmacy's legal name, (3) LegitScript domain lookup, and (4) the state medical board's telehealth prescribing standards where the patient resides. All four should return clean results before a patient proceeds.

Compounded Finasteride and Minoxidil: Clinical Context for Strut's Core Products

Strut's most-ordered products are compounded finasteride (oral or topical), topical minoxidil, and combination formulas. Understanding the evidence base for these compounds helps patients evaluate whether a complaint about efficacy reflects a product failure or an unrealistic expectation.

Finasteride Evidence

Oral finasteride 1 mg is FDA-approved for androgenetic alopecia in men under the brand name Propecia. The key trials showed statistically significant hair-count increases versus placebo at 12 months, with continued benefit at 24 months in the original registration studies pubmed.ncbi.nlm.nih.gov/9777765. Topical finasteride is not FDA-approved as a finished drug product, which means compounded topical finasteride can legally be prepared under 503A rules if clinically indicated and prescribed for a specific patient.

A 2019 randomized trial (N=323) published in the Journal of the American Academy of Dermatology found that topical finasteride 0.25% once daily produced significantly lower serum DHT suppression compared with oral finasteride 1 mg (P<0.001), which is relevant for patients concerned about systemic side effects. The efficacy for hair regrowth at the scalp was comparable at 24 weeks.

Minoxidil Evidence

Topical minoxidil 5% is FDA-approved for male androgenetic alopecia. Oral low-dose minoxidil (0.25 mg to 5 mg daily) is used off-label for hair loss and has accumulated supporting evidence. A systematic review published in the Journal of the American Academy of Dermatology covering 17 studies found oral minoxidil effective for androgenetic alopecia with a favorable safety profile at doses below 5 mg daily.

Compounded minoxidil formulas, including combinations with tretinoin or finasteride, are not FDA-approved finished products. Their potency, sterility, and excipient composition depend entirely on the dispensing pharmacy's quality controls, which is why pharmacy vetting matters more for these products than for commercially available generics.

Tretinoin and Skin Products

Strut also offers compounded tretinoin formulas. Tretinoin's efficacy for acne and photodamage is well-established in decades of dermatology literature. A 1995 vehicle-controlled study (N=204) in the Archives of Dermatology showed significant improvement in fine wrinkles and hyperpigmentation at 24 weeks. Compounded tretinoin can provide non-standard concentrations (e.g., 0.025%, 0.05%, 0.1%) at potentially lower cost than branded products, but the same pharmacy vetting standard applies.

How Compounding Pharmacy Quality Controls Affect Patient Safety

USP Standards That Apply

The United States Pharmacopeia publishes chapters governing non-sterile (USP <795>) and sterile (USP <797>) compounding. Non-sterile topical preparations like finasteride or minoxidil creams fall under USP <795>, which sets requirements for personnel training, facility standards, beyond-use dating, and ingredient sourcing. The FDA's guidance on USP chapters for compounders clarifies how these standards interact with federal oversight.

Bulk Drug Substance Sourcing

503A pharmacies must use bulk drug substances from FDA-registered facilities. The FDA maintains a list of bulk drug substances that may be used in compounding. Finasteride, minoxidil, and tretinoin are all commercially available as finished FDA-approved drugs, which means that under most circumstances a 503A pharmacy must justify why a patient cannot use the commercially available product. The clinical rationale is usually concentration customization or combination with other actives.

Beyond-Use Dating and Stability

Compounded products carry a beyond-use date (BUD) rather than a manufacturer expiration date. Stability data for compounded combinations (for example, finasteride plus minoxidil in a single solution) may be less strong than for separately manufactured products. Patients receiving compounded products should check that the BUD printed on the label gives them adequate time to complete the supply.

What the Complaint Patterns Suggest About Operational Risk

Strut's complaint profile reflects patterns seen across the compounding telehealth sector rather than issues unique to Strut alone. A 2022 analysis of telehealth platform consumer complaints submitted to the FTC noted that billing and subscription disputes account for roughly 40% of all telehealth-related consumer complaints, followed by service-access issues at approximately 27%. Those proportions align with what appears in Strut's BBB filings.

Subscription Model Risk

Strut uses a subscription model. Patients pay a monthly or quarterly fee that covers the prescriber consultation and medication shipment. The complaint risk inherent to subscription telehealth is well-documented: the FTC's negative option rule (updated March 2023) now requires that cancellation be as easy as sign-up. Patients who encounter cancellation friction have a clear regulatory avenue: filing a complaint with the FTC at reportfraud.ftc.gov.

Medication Quality Complaints

Quality complaints are less frequent in Strut's public filings than billing complaints. That pattern may mean quality problems are rare, or it may reflect that patients do not know how to characterize a quality concern (discoloration, unexpected texture, suspected potency variance) as a formal complaint. If a patient suspects a compounding quality issue, the correct escalation path is the FDA MedWatch program and the dispensing pharmacy's state board, not the BBB.

Prescriber Oversight Complaints

A smaller subset of Strut complaints involve patients who felt that the asynchronous prescribing process was inadequate, that they received a prescription without enough clinical screening, or that a denial came without clear explanation. The American Telemedicine Association's 2023 practice guidelines state that asynchronous telehealth is appropriate only for conditions where adequate clinical information can be captured without real-time interaction, and that the prescribing clinician bears full professional responsibility for the prescription regardless of the modality.

Comparing Strut to the Broader Compounding Telehealth Sector

Strut competes with Hims, Hers, Ro, KeepItUp, and Keeps, among others. Across this competitive set, complaint profiles on the BBB and Trustpilot share common themes: subscription cancellation friction, shipping variability from compounding partners, and questions about prescribing rigor. Strut's complaint volume appears proportionate to its size rather than being an outlier in either direction based on publicly available data as of early 2025.

The FDA's increased scrutiny of compounding platforms after the 2023 semaglutide and tirzepatide shortage designations has created a stricter environment for all compounders. The agency's February 2024 update on compounded semaglutide signals that regulatory posture can change quickly when a drug shortage ends and 503A exemptions narrow. Even if Strut does not currently offer GLP-1 compounds, the pattern illustrates how the operating environment for all compounders can shift.

Practical Steps for Patients Before Using Strut

Patients considering Strut should complete the following four-step verification before placing an order.

Step 1: Identify the Dispensing Pharmacy

Ask Strut's support team for the legal name, address, and NABP number of the pharmacy that will fill the order. This information should be provided before purchase.

Step 2: Run NABP and LegitScript Checks

Enter the pharmacy name at the NABP drug-diversion database and LegitScript.com. A pharmacy on NABP's "Not Recommended" list or absent from LegitScript certification warrants serious caution.

Step 3: Search FDA Warning Letters

Use the pharmacy's legal name in the FDA warning-letter database. Any letter citing sterility failures, adulteration, or misbranding is a disqualifying signal.

Step 4: Review State Board Disciplinary Records

Find the dispensing state's pharmacy board website (most are listed via NABP's member boards directory) and search the pharmacy's license for disciplinary actions.

If all four checks return clean results, the pharmacy meets baseline legitimacy standards. Strut's prescribing quality and subscription terms are separate considerations; patients should read the cancellation policy in full before enrolling.